Phase 3 Readout
CADL: Phase 3 Topline: A Phase 3, Multicenter, Randomized, Controlled, Open-Label Clinical Trial of Aglatimagene Besadenove
October 22, 2031 · aglatimagene. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 22, 2031
- Company
- Candel Therapeutics, Inc. (CADL)
- Drug
- aglatimagene
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3, Multicenter, Randomized, Controlled, Open-Label Clinical Trial of Aglatimagene Besadenove
- Drug
- aglatimagene
- Indication
- Non-squamous, Non-Small Cell Lung Cancer